Document Detail

Heated, humidified high-flow nasal cannula versus nasal CPAP for respiratory support in neonates.
MedLine Citation:
PMID:  23610207     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND OBJECTIVE: Heated, humidified high-flow nasal cannula (HHHFNC) is commonly used as a noninvasive mode of respiratory support in the NICU. The safety and efficacy of HHHFNC have not been compared with other modes of noninvasive support in large randomized trials. The objective was to assess the efficacy and safety of HHHFNC compared with nasal continuous positive airway pressure (nCPAP) for noninvasive respiratory support in the NICU.
METHODS: Randomized, controlled, unblinded noncrossover trial in 432 infants ranging from 28 to 42 weeks' gestational age with planned nCPAP support, as either primary therapy or postextubation. The primary outcome was defined as a need for intubation within 72 hours of applied noninvasive therapy.
RESULTS: There was no difference in early failure for HHHFNC (23/212 [10.8%]) versus nCPAP (18/220 [8.2%]; P = .344), subsequent need for any intubation (32/212 [15.1%] vs 25/220 [11.4%]; P = .252), or in any of several adverse outcomes analyzed, including air leak. HHHFNC infants remained on the study mode significantly longer than nCPAP infants (median: 4 vs 2 days, respectively; P < .01), but there were no differences between study groups for days on supplemental oxygen (median: 10 vs 8 days), bronchopulmonary dysplasia (20% vs 16%), or discharge from the hospital on oxygen (19% vs 18%).
CONCLUSIONS: Among infants ≥28 weeks' gestational age, HHHFNC appears to have similar efficacy and safety to nCPAP when applied immediately postextubation or early as initial noninvasive support for respiratory dysfunction.
Bradley A Yoder; Ronald A Stoddard; Ma Li; Jerald King; Daniel R Dirnberger; Soraya Abbasi
Related Documents :
3573257 - A mass vaccination program in taiwan against hepatitis b virus infection in infants of ...
24579507 - Congenital lobar emphysema in a nigerian neonate: a rare cause of neonatal respiratory ...
24358887 - Presentation of an umbilical cord cyst with a surprising jet: a case report of a patent...
18505437 - Salivary human immunodeficiency virus (hiv)-1-specific immunoglobulin a in hiv-1-expose...
22591907 - Omega 3 fatty acids on child growth, visual acuity and neurodevelopment.
3362157 - Mutagen-induced fetal anomalies and death following treatment of females within hours a...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial     Date:  2013-04-22
Journal Detail:
Title:  Pediatrics     Volume:  131     ISSN:  1098-4275     ISO Abbreviation:  Pediatrics     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-05-02     Completed Date:  2013-07-17     Revised Date:  2013-10-21    
Medline Journal Info:
Nlm Unique ID:  0376422     Medline TA:  Pediatrics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e1482-90     Citation Subset:  AIM; IM    
Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT 84158-1289, USA.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Catheterization, Peripheral / instrumentation*,  methods
Continuous Positive Airway Pressure / instrumentation*,  methods*
Follow-Up Studies
Gestational Age
Hospital Mortality / trends
Hot Temperature / therapeutic use
Infant, Newborn
Infant, Premature*
Intensive Care Units, Neonatal
Intermittent Positive-Pressure Ventilation / instrumentation,  methods*
Noninvasive Ventilation / methods,  mortality
Oxygen / therapeutic use
Prospective Studies
Respiratory Distress Syndrome, Newborn / diagnosis,  mortality*,  therapy*
Risk Assessment
Statistics, Nonparametric
Survival Rate
Treatment Outcome
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Benefits of universal gloving on hospital-acquired infections in acute care pediatric units.
Next Document:  Survival of Patients With Spinal Muscular Atrophy Type 1.